Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...

Sequence variations in human immunodeficiency virus (HIV)-1 reverse transcriptase (RT) and protease, the molecular targets of anti-retroviral drug therapy, are prime examples of genes in which ...

自从人类免疫缺陷病毒 (HIV)于20世纪80年代初初次被发现，迄今近半个世纪已经过去了，人类仍然未能获得一种有效的艾滋病 疫苗。目前全球的疫苗学家们面临的最大挑战之一就是开发有效的艾滋病疫苗。

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

It is an ester-derived prodrug that is converted in vivo by serum and tissue esterases to tenofovir, an acyclic nucleoside phosphonate (nucleotide) that inhibits HIV reverse transcriptase.

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

The four main classes, which most people are treated with, target one of three viral proteins which control HIV’s lifecycle: reverse transcriptase, integrase and protease. Historically, most people ...

Generally, the dual NRTI backbone treatment of combination with a non-NRTI (NNRTI) or protease inhibitor (PI) should comprise a cytidine analogue (lamivudine, emtricitabine) and a thymidine ...

For this purpose, anti-HIV drugs target essential viral proteins in the replication cycle of HIV, mostly the viral reverse transcriptase and protease. Unfortunately, HIV is highly variable and ...

Researchers at The University of Texas MD Anderson Cancer Center have made a groundbreaking discovery in the fight against ...

The following is a summary of “High-density lipoprotein anti-inflammatory capacity and acute kidney injury after cardiac and ...